文献速递放疗物理与技术姑息放疗与转移瘤

儿童癌症幸存者不良事件的放射剂量-体积-反应关系:PENTEC科学问题介绍

Radiation Dose-Volume-Response Relationships for Adverse Events in Childhood Cancer Survivors: Introduction to the Scientific Issues in PENTEC.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-01-01

本文介绍PENTEC协作网络旨在基于文献总结并综合儿童癌症幸存者(CCS)不良事件的剂量-体积-反应关系,并系统讨论儿童正常组织临床放射生物学面临的七大挑战,包括儿童肿瘤罕见且异质、不良事件非放疗特异、研究设计与风险表达多样、潜伏期长达30至50年以上、需回顾性剂量学、多因素影响及前瞻性数据库建设。

要点

  • PENTEC协作网络旨在基于文献总结并综合儿童癌症幸存者不良事件的剂量-体积-反应关系。
  • 儿童肿瘤约占美国新发癌症的1%,生物学异质导致文献多为小系列且系列间变异大。
  • CCS不良事件常发生于治疗后30、50年或更久,终身风险估计通常为依赖数学模型的 extrapolation。

核心结论

  • PENTEC协作网络旨在基于文献总结并尽可能综合儿童癌症幸存者一系列不良事件的剂量-体积-反应关系。
  • 儿童正常组织临床放射生物学面临多重挑战,本文讨论这些挑战及在PENTEC框架下克服它们的尝试。

研究设计与样本

  • 本文为PENTEC协作网络的方法学介绍,基于文献总结并综合儿童癌症幸存者不良事件的剂量-体积-反应关系。

主要发现

  • 儿童恶性肿瘤相对罕见,约占美国新发癌症的1%,且生物学异质,导致文献多为小系列且系列内与系列间变异大。
  • CCS面临一系列非放疗特异的不良健康事件风险升高,因此与参考人群比较的 excess relative or absolute risk 成为合适指标。
  • 文献中存在多种研究设计和风险表达量,本文对此进行了总结。
  • CCS不良效应常在治疗后30、50年或更久发生,即使随访很长的系列其信息量也有限,终身风险估计通常为依赖所用数学模型的 extrapolation。
  • 长潜伏期意味着需要回顾性剂量学,因为基于个体CT的放疗计划在1980年后才逐渐可用。

局限性

  • 儿童恶性肿瘤相对罕见,约占美国新发癌症的1%,且生物学异质,导致文献多为小系列且系列内与系列间变异大,给跨系列数据综合带来挑战。
  • CCS面临一系列非放疗特异的不良健康事件风险升高,因此需采用与参考人群比较的 excess relative or absolute risk 作为指标。
  • 文献中存在多种研究设计和风险表达量。
  • CCS不良效应常在治疗后30、50年或更久发生,即使随访很长的系列其信息量也有限,终身风险估计通常为依赖所用数学模型的 extrapolation。
  • 长潜伏期意味着需要回顾性剂量学,因为基于个体CT的放疗计划在1980年后才逐渐可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

At its very core, radiation oncology involves a trade-off between the benefits and risks of exposing tumors and normal tissue to relatively high doses of ionizing radiation. This trade-off is particularly critical in childhood cancer survivors (CCS), in whom both benefits and risks can be hugely consequential due to the long life expectancy if the primary cancer is controlled. Estimating the normal tissue-related risks of a specific radiation therapy plan in an individual patient relies on predictive mathematical modeling of empirical data on adverse events. The Pediatric Normal-Tissue Effects in the Clinic (PENTEC) collaborative network was formed to summarize and, when possible, to synthesize dose-volume-response relationships for a range of adverse events incident in CCS based on the literature. Normal-tissue clinical radiation biology in children is particularly challenging for many reasons: (1) Childhood malignancies are relatively uncommon-constituting approximately 1% of new incident cancers in the United States-and biologically heterogeneous, leading to many small series in the literature and large variability within and between series. This creates challenges in synthesizing data across series. (2) CCS are at an elevated risk for a range of adverse health events that are not specific to radiation therapy. Thus, excess relative or absolute risk compared with a reference population becomes the appropriate metric. (3) Various study designs and quantities to express risk are found in the literature, and these are summarized. (4) Adverse effects in CCS often occur 30, 50, or more years after therapy. This limits the information content of series with even very extended follow-up, and lifetime risk estimates are typically extrapolations that become dependent on the mathematical model used. (5) The long latent period means that retrospective dosimetry is required, as individual computed tomography-based radiation therapy plans gradually became available after 1980. (6) Many individual patient-level factors affect outcomes, including age at exposure, attained age, lifestyle exposures, health behaviors, other treatment modalities, dose, fractionation, and dose distribution. (7) Prospective databases with individual patient-level data and radiation dosimetry are being built and will facilitate advances in dose-volume-response modeling. We discuss these challenges and attempts to overcome them in the setting of PENTEC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Bentzen SM, Vogelius IR, Hodgson D, et al. Radiation Dose-Volume-Response Relationships for Adverse Events in Childhood Cancer Survivors: Introduction to the Scientific Issues in PENTEC. Int J Radiat Oncol Biol Phys. 2024. PMID: 38760115. doi:10.1016/j.ijrobp.2023.11.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。